logo
MRI Reveals Joint Damage After Cancer Treatment

MRI Reveals Joint Damage After Cancer Treatment

Medscape27-06-2025
TOPLINE:
According to a UK study, whole-body MRI showed that patients with arthralgia who had previously received immune checkpoint inhibitor therapy had similar levels of inflammation and erosions as those with clinical arthritis, with distinct imaging patterns.
METHODOLOGY:
Researchers recruited 60 adults (mean age, 65 years; 43% women; 100% White) with new musculoskeletal symptoms during or within 6 months after receiving treatment with immune checkpoint inhibitors and 20 healthy control individuals (mean age, 62 years; 40% women; 100% White) from the UK, who underwent gadolinium contrast-enhanced whole-body MRI.
A total of 35 patients had arthralgia and 25 had inflammatory arthritis.
Two independent masked assessors graded joint, tendon, bursal, entheseal, and whole spinal imaging lesions, with consensus reporting and a 6-month follow-up.
TAKEAWAY:
Distinct global inflammatory patterns were identified on the MRI scans: polymyalgia rheumatica (extracapsular; 12%), peripheral inflammatory arthritis (37%), spondyloarthropathy (n = 1), and a non-specific pattern (20%).
Median total appendicular joint synovitis, joint erosion, enthesitis, and tenosynovitis scores were significantly higher in both arthralgia and inflammatory arthritis groups than in control individuals, with no significant differences found between the arthralgia and inflammatory arthritis subgroups.
Among the patients exposed to immune checkpoint inhibitors, acromioclavicular (77%), glenohumeral (75%), wrist (73%), and metacarpophalangeal (59%) joints were most frequently affected by synovitis.
Patients with a peripheral inflammatory arthritis pattern were most likely to require disease-modifying antirheumatic drug therapy, showing the highest initial and ongoing glucocorticoid requirement.
IN PRACTICE:
"[The study] results suggest that the overall burden of musculoskeletal toxicity associated with immune checkpoint inhibitors is currently under-recognised and highlights the range and extent of inflammation in all patients presenting with new musculoskeletal symptoms after exposure to an immune checkpoint inhibitor. Rheumatology assessment should be considered by oncologists for patients who develop arthralgia alone," the authors wrote.
SOURCE:
This study was led by Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, England. It was published online on June 10, 2025, in The Lancet Rheumatology.
LIMITATIONS:
Feet and ankles were not imaged during the study due to logistical constraints. The 6-month follow-up period was relatively short for determining long-term musculoskeletal outcomes. Some patients were classified as having non-specific inflammation patterns, whose significance was unclear. A few participants had preexisting autoimmune diseases, possibly increasing their baseline risk for arthritis. Additionally, intra-assessor agreement was not measured.
DISCLOSURES:
This study received support from the National Institute for Health and Care Research Leeds Biomedical Research Centre. One author reported receiving a EULAR bursary travel award, and some authors reported having financial ties with various sources. Details are provided in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I'm A 52-Year-Old Trainer, And I Think This 15-Minute Routine Is The 'Only' Arms Workout Women Need
I'm A 52-Year-Old Trainer, And I Think This 15-Minute Routine Is The 'Only' Arms Workout Women Need

Yahoo

timean hour ago

  • Yahoo

I'm A 52-Year-Old Trainer, And I Think This 15-Minute Routine Is The 'Only' Arms Workout Women Need

If anyone can tell you how to get results from your workouts, it's Caroline Idiens. At 52, she has over 20 years of experience as a personal trainer, including five years heading up her online fitness platform Caroline's Circuits, specializing in 30-minute home strength workouts. But half of that time is enough to build your arms, Idiens says. "This may be controversial, but I think (know) this is the ONLY arms workout you need at home," she says of her go-to 15-minute routine. "All you need are a set of dumbbells. Take a 30-sec rest between exercises and try three sets in total. Go slow and warm up first. I'm using 5 kgs, but use the weight that is right for you." Here's exactly which exercises to do and how many reps to go for... Best 15-minute arm workout for women Around the worlds. Do: 10 reps x 3 Hold a kettlebell or dumbbell with both hands, keeping your arms extended in front of you. Stand with feet shoulder-width apart, maintaining a stable and upright posture. Initiate the movement by passing the weight around your body, from front to back, in a circular motion. Keep the movement fluid and controlled, maintaining a stable core front raises. Do: 12 reps x 3 Stand with your feet hip-width apart, holding a dumbbell in each hand with palms facing your body. Keep your arms straight (with a slight bend in the elbows) and lift one arm forward and up to shoulder height, while keeping the other arm at your side. Lower the raised arm with control and repeat on the opposite side. That's one rep; alternate sides for the total number of raises. Do: 10 reps x 3 Stand with a dumbbell in each hand, arms by your sides, palms facing inwards. Ensure your shoulders are relaxed (not raised), your abs are engaged (think tensing, as opposed to breathing in), and there's a slight bend in your knees. Retaining this posture, lift the dumbbells out to the sides with straight arms, going no higher than shoulder height. Gradually (i.e. don't just let your arms fall back down, move with control) lower the dumbbells to the starting shoulder press. Do: 12 reps x 3 Stand with feet shoulder-width apart, holding a dumbbell in each hand at shoulder height with palms facing each other. A Alternately press one dumbbell overhead, extending the arm fully, while keeping the other dumbbell at shoulder height. Lower the raised arm back to the starting position and repeat on the other side, continuing to flies. Do 10 reps x3 Stand with your feet at a hip-width distance with a soft bend in your knees. With a neutral spine, hinge at the waist so your chest is lowered to near parallel with the floor and your hips come slightly backwards. With your arms straight down towards the floor, hold the dumbbells comfortably in your hands with a neutral grip (palms facing in towards each other). Have a soft bend in your elbows as you raise the weights up and out to the sides, in line with your shoulders; at this point, your palms should be facing down to the floor. Squeeze your upper back and in between your shoulder blades to assist the movement. Control the movement as you lower the weights back to the starting kickbacks. Do: 12 reps x 3 Stand with your knees bent and lean forward slightly, with a dumbbell in each hand. Keeping your back straight, bend your dumbell-holding arm 90 degrees at the elbow so your triceps are aligned with your back and your biceps are perpendicular to the floor. Engage your core and your triceps and hinge at the elbow, lifting the dumbbell up and back as you try and straighten your arm. Your triceps should stay still; only your elbow moves. Guide the weight upward until your arm is straight, pause, then lower back to 90 degrees. That's one curls. Do 10 reps x 3 Stand with your feet hip-width apart, holding weights in front of you, palms facing forward. Without moving your upper arms, slowly curl the weights toward your shoulders. At the top of the curl, rotate your wrists inward so your palms face forward. Slowly lower them in that position. Rotate your wrists and dumbbells back to the starting position. That's one Arnold press. Do: 8 each side x 3 Take a dumbbell in each hand. Stand with a shoulder-width stance and brace your core. Raise the dumbbells so they're shoulder height with your palms facing your body. Pull your shoulder blades back and down, then extend your arms up while rotating your wrists to the front, so that you end up with the dumbbells above your head with palms facing forward. Remaining stable, slowly lower the dumbbells and rotate the wrists so that the palms are facing towards you chest press. Do: 8 reps x 3 Stand with feet shoulder-width apart, holding a dumbbell in each hand at shoulder height, palms facing forward. Keeping your arms bent, bring your elbows and palms to touch while holding the dumbbells in the same position. Then open your arms back to the starting position, maintaining the same angle. That's one rep. Get the Workouts Get the Challenge Get the Workouts Get the Workouts Get the Challenge Get the Workouts Get the Challenge Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Challenge Get the Workouts You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals

ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency
ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency

Yahoo

timean hour ago

  • Yahoo

ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the . On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK's Medicines and Healthcare products Regulatory Agency has approved ANKTIVA with Bacillus Calmette-Guérin for treating certain bladder cancer patients. This is significant as it marks the first approval for the company outside of the United States of America. Moreover, the drug is a first-in-class IL-15 agonist, which works by activating and multiplying immune cells, specifically NK cells and T cells that help the body fight cancer. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. In addition, clinical studies have shown strong results as some patients maintained a complete response for over 47 months at the last review. ImmunityBio, Inc. (NASDAQ:IBRX) is a biopharmaceutical company that develops therapies and vaccines that boost the immune system to fight cancer and infectious diseases. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

Yahoo

timean hour ago

  • Yahoo

OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

OPKO Health, Inc. (NASDAQ:OPK) is one of the . On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This new therapy is a first in class and combines OPKO Health, Inc.'s (NASDAQ:OPK) long-acting GLP-2 agonist with Entera's N-Tab technology. The display will be in the Forum Hall Foyer 3, focusing on liver and gastrointestinal tract topics. The therapy treats short bowel syndrome, which is a condition where patients struggle to absorb nutrients due to a damaged or shortened intestine. Currently, the only approved treatment is GATTEX, which requires patients to inject themselves once a day. The oral GLP-2 tablet could change this. It aims to provide the same benefits without painful injections. This format may improve patient compliance and comfort. A doctor in scrubs discussing a patient's test results with a small group of concerned family members. OPKO Health, Inc. (NASDAQ:OPK) is an international biopharmaceutical company that develops and sells medicines, including human growth hormone and treatments for kidney disease. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store